Early Screen and Treatment for Gestational Diabetes
Gestational Diabetes Mellitus: Does Early Screening and Treatment for Patients at Increased Risk for Gestational Diabetes Impact Perinatal Outcomes? A Randomized Controlled Trial
調査の概要
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Florida
-
Tampa、Florida、アメリカ、33606
- USF Health South Tampa Center for Advanced Healthcare
-
Tampa、Florida、アメリカ、33610
- TGH Health Park Genesis Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Pregnant subjects 18-45 y/o and Any of the following:
Obesity defined as having a BMI>30 kg/m2 History of pregnancy complicated with GDM History of pregnancy complicated with macrosomia First degree relative with diabetes Multiple gestation
Exclusion Criteria:
- Incomplete Data: if any data is missing (i.e Delivery data) , analysis cannot be completed.
Pregnancy complicated with fetal malformations or aneuploidy: It affects prenatal care, mode of delivery as well as perinatal outcome.
Pregestational or Overt Diabetes: Patients with Diabetes cannot be diagnosed with GDM.
Chronic medical conditions such as hypertension, renal disease, autoimmune conditions: Those conditions may affect prenatal care, perinatal morbidity.
Early diabetes screen performed prior to enrollment in study: Participant cannot be randomized, and probably have been treated.
Medical contraindication to glucose tolerance test (bariatric surgery): patients with h/o gastric bypass frequently cannot tolerate oral glucose load, therefore cannot be screened for GDM in the traditional way.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：Early glucose screen group
Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load.
If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
|
Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
|
|
他の：Standard glucose screen group
The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
|
Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite Perinatal morbidity
時間枠：up to 28 days after birth
|
The primary study outcome is a composite of perinatal morbidities including perinatal mortality (stillbirth or neonatal death), neonatal hypoglycemia, hyperbilirubinemia, and birth trauma.
Transcutaneous bilirubin is routinely measured at Tampa General Hospital (TGH) on all babies at least once.
A value greater than the 95th percentile for or need for phototherapy at any given point after birth will be considered an elevated level.
Birth trauma is defined as brachial plexus palsy or clavicular, humeral, or skull fracture.
|
up to 28 days after birth
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Maternal weight gain
時間枠：up to delivery
|
up to delivery
|
協力者と研究者
捜査官
- 主任研究者：Alejandro Rodriguez, MD、University of South Florida
- スタディチェア：Judette Louis, MD, MPH、University of South Florida
- スタディディレクター：Linda Odibo、University of South Florida
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。